Drug Database
IM

immunoglobulin G

✓ Approved

Quimbiotec · Polyclonal Antibodies · Polyclonal Antibodies

What is immunoglobulin G?

immunoglobulin G is a polyclonal antibodies developed by Quimbiotec. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyQuimbiotec
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Quimbiotec

Therapeutic Indications

immunoglobulin G is developed for 4 unique indications across 4 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersGuillain-Barre syndrome✓ Approved
Skin and subcutaneous tissue disordersPurpura✓ Approved
Immune system disordersImmunodeficiency✓ Approved
Infections and infestationsBorna virus infection✓ Approved

Related Research Articles

PubMedAnimals : an open access journal from MDPI2026-10-16

The Effects of Chicory Aqueous Extract on Antioxidant Capacity, Immune Response, and Intestinal Function in Broilers.

Wei Mingyu M, Li Mengfei M, Li Zehao Z, Liu Hao H et al.

In the broiler production industry, antibiotics such as florfenicol are widely used. Although these antibiotics exert therapeutic effects against bacterial diseases, they can induce a series of physiological alterations in broilers under certain exposure scenarios. This study aimed to investigate the effects of chicory aqueous extract (CAE) on broiler growth performance, immune function, and intestinal health, and to compare the impacts of CAE and florfenicol exposure on the physiological status of broilers. A total of 200 one-day-old broilers were randomly divided into five groups (5 replicates per group): the blank control group (NC) drank tap water freely, the florfenicol group (FFC) was given 0.15 g/L of florfenicol solution in the drinking water, the CAE groups were given 1.25 g/L (LCAE), 2.5 g/L (MCAE), and 5 g/L (HCAE) of CAE in the drinking water, respectively. The experimental period was 42 days. The results showed that the addition of CAE to drinking water could significantly improve the growth performance of broilers, specifically manifested as increased body weight and a significantly decreased feed-to-gain ratio (F/G) (p < 0.05). Regarding immune function, CAE enhanced immune capacity by increasing immune organ indices, serum antibody titers, and serum levels of immunoglobulin A (IgA) and immunoglobulin G (IgG) (p < 0.05). In terms of intestinal function, CAE significantly increased villus height (VH) and villus-crypt ratio (V/C), elevated activities of digestive enzymes including chymotrypsin, α-amylase, and lipase, and raised both secretory immunoglobulin A (sIgA) content and Occludin mRNA relative expression levels (p < 0.05), thereby improving intestinal digestion and absorption. Additionally, CAE enhanced serum superoxide dismutase (SOD) activity and reduced malondialdehyde (MDA) content (p < 0.05), effectively enhancing the antioxidant capacity of broilers. Notably, compared with the NC group and all CAE-treated groups, broilers in the FFC group exhibited significantly reduced growth performance, suppressed immune function, and evident damage to intestinal tissue structure and physiological functions. Comprehensive analysis indicates that CAE can effectively promote broiler growth and development, enhance immune status and intestinal digestive-absorptive function, and enrich gut bacteria such as Lactobacillus and Bifidobacterium, thus optimizing intestinal microbiota composition. Among the gradient doses tested in this study, the 2.5 g/L dose of CAE demonstrated the best overall effect, suggesting that CAE may exert beneficial physiological effects under the present experimental conditions, and further investigations are needed to assess its practical application potential.

PMID 42883033
Read full article →
PubMedClinical and translational gastroenterology2026-10-16

Immunoglobulin G and liver stiffness in autoimmune hepatitis: Timing matters more than biochemical correction.

Niezen Sebastian S, Goyes Daniela D, Abadi-Ron Victoria V, Rojas Amaris Natalia N et al.

Transient elastography may overestimate fibrosis in autoimmune hepatitis (AIH) because hepatic inflammation independently increases liver stiffness measurement (LSM). We aimed to determine which inflammation markers confound LSM in AIH, whether algebraic correction improves accuracy, and when LSM becomes reliable for fibrosis staging. Single-center retrospective cohort of adults with AIH, paired diagnostic Metavir biopsy, and at least one FibroScan visit with same-visit alanine aminotransferase (ALT) and immunoglobulin G (IgG). Mixed-effects linear regression modeled LSM on biopsy stage, ALT, IgG, and time since diagnosis with a patient-level random intercept. An inflammation-adjusted LSM was computed by subtracting estimated ALT and IgG contributions. Spearman correlation and DeLong-tested AUROC for advanced fibrosis (F3-F4) compared measured and adjusted LSM, stratified by inflammation state and treatment timing. We analyzed 208 FibroScan observations from 119 AIH patients (49 with advanced fibrosis). IgG was independently associated with LSM (β = +0.003 kPa per mg/dL, p < 0.001) while ALT was not (β ≈ 0, p = 0.68). The IgG-LSM relationship varied by treatment timing (IgG × 0-6 months interaction p = 0.001; IgG × 12-24 months p = 0.004). Algebraic correction did not improve discrimination (full-cohort AUROC measured 0.76 vs adjusted 0.72, DeLong p = 0.18). LSM accuracy for advanced fibrosis varied by timing: AUROC 0.71 pretreatment (n = 35), 0.64 at 12-24 months (n = 22), and 0.83 beyond 24 months (n = 72). In AIH, IgG-not ALT-independently inflates LSM, with a time-dependent effect strongest early after diagnosis. Algebraic correction did not improve fibrosis discrimination, but LSM accuracy improved substantially beyond 24 months after AIH diagnosis. Timing rather than algebraic correction is the more actionable clinical strategy for FibroScan interpretation in AIH.

PMID 42886068
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Essential Oil-Containing Mouthrinses for Plaque and Gingivitis Control: Formulation Chemistry, Human Salivary Biomarkers, Mechanistic Evidence, and Research Priorities.

Sytykiewicz Hubert H

Selected essential oil (EO)-containing mouthrinses improve plaque and gingivitis control when used alongside mechanical oral hygiene, but their molecular effects in human saliva remain poorly defined. This narrative review integrates formulation chemistry, oral exposure, human salivary evidence, and mechanistic studies. Three studies identified in this review evaluated salivary immunoglobulin A, immunoglobulin G, or interleukin-1β. Differences in populations, co-interventions, sampling, and analytical methods limit comparison and do not establish reproducible modulation of a single biomarker. Other human studies assessed salivary flow, pH, proteomic responses, microbial counts, nitrate reduction, and oral biofilms. Mechanistic evidence largely derives from isolated constituents in cellular, animal, or computational models. A study of a complete zinc-containing formulation in human oral cells provides formulation-level evidence, but neither this study nor the constituent literature establishes target engagement after mouthrinsing in humans. Future trials should connect chemically characterized formulations and measured oral exposure with target-specific assays, validated salivary endpoints, microbial function, clinical outcomes, and safety. Current evidence supports selected formulations for plaque and gingivitis control; it does not establish an EO class effect or a validated salivary mechanism of clinical benefit.

PMID 42883182
Read full article →
PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-10-16

High Prevalence of Oxford MEST-C Lesions in Immunoglobulin A Nephropathy of Kidney Allografts: A Single-Center Study from Viet Nam.

Thai Kinh Luan KL, La Ngoc Thu Nguyen NTN, Hoang Tien Dat TD, Duong Nguyen Xuong NX et al.

We evaluated the clinical characteristics, Oxford 2016 histopathology features, and short-term outcomes of Immunoglobulin A nephropathy in kidney transplant recipients at Cho Ray Hospital, Ho Chi Minh City, Viet Nam. This retrospective, descriptive study included kidney transplant recipients with biopsy -proven immunoglobulin A nephropathy in kidney allografts identified in 2022. We analyzed patient death with a functioning graft as a competing event and not classified as graft failure. Immunoglobulin A nephropathy was present in 27.1 % (19/70 ) of allograft biopsies. Most recipients were male (73.7 %) and received grafts from living related donors (17 /19, 89.4 % ). The mean time from transplant to immunoglobulin A nephropathy diagnosis was 5.2 years. Median follow -up after biopsy was 48 weeks. Three components of the Oxford MEST -C were frequently observed, that is, mesangial hypercellularity M1 (73.7 % ), segmental glomerulosclerosis S1 (78.9 % ), and cellular /fibrocellular crescents C1 (26.3 % ). At the end of follow -up, 68.4 % of patients maintained graft function, 15.8 % required hemodialysis, and 10.5 % died from nonrenal causes with functioning grafts. Immunoglobulin A nephropathy was frequently observed in our patient cohort; however, the inability to distinguish recurrent disease from de novo disease fundamentally limited interpretation of the histopathology patterns. Moreover, given the short -term and multifactorial nature of the outcomes, together with the limitations of the Oxford MEST -C in the allograft setting, the independent prognostic significance of these lesions remains uncertain and requires further validation through larger prospective studies.

PMID 42885704
Read full article →
PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-10-16

Hepatitis B Virus Recurrence After Liver Transplant for Hepatitis B Virus-Related Liver Disease: A Retrospective Analysis of Hepatitis B Immunoglobulin Discontinuation.

Aktuna Hakan H, Daniş Nilay N, Döngelli Hüseyin H, Bacakoğlu Aylin A et al.

Hepatitis B virus recurrence after liver transplant remains a clinically relevant issue, but the optimal duration and safety of hepatitis B immunoglobulin therapy, particularly its discontinuation, remain unclear. Here, we evaluated the incidence and risk factors of posttransplant hepatitis B virus recurrence and assessed outcomes following elective discontinuation of hepatitis B immunoglobulin in a real-world cohort. We conducted a retrospective single-center cohort study of consecutive adult patients who underwent liver transplant for hepatitis B virus-related liver disease between 1997 and 2023. Hepatitis B virus recurrence was defined as the reappearance of hepatitis B surface antigen and/or detectable hepatitis B virus DNA. We used Cox proportional hazards models to identify factors associated with recurrence and overall survival. We conducted a predefined subgroup analysis to evaluate patients who underwent elective discontinuation of hepatitis B immunoglobulin during antiviral therapy. Among 254 liver transplant recipients, 39 (15.4% ) developed posttransplant hepatitis B virus recurrence. In multivariable analysis, pretransplant hepatitis B virus DNA levels >5 log10 copies/mL (hazard ratio 3.68; 95% CI, 1.82-7.46) and hepato-cellular carcinoma at transplant (hazard ratio 2.38; 95% CI, 1.22-4.65) were independently associated with recurrence, whereas hepatitis D virus coinfection was inversely associated (hazard ratio 0.18; 95% CI, 0.08-0.43). Elective hepatitis B immunoglobulin discontinuation was not associated with increased hepatitis B virus recurrence and was primarily performed in clinically selected low-risk patients. Posttransplant hepatitis B virus recurrence was associated with reduced overall survival. In this long-term, real-world cohort, posttransplant hepatitis B virus recurrence was mainly driven by the pretransplant viral burden and oncological factors. Elective hepatitis B immunoglobulin discontinuation in carefully selected patients was not associated with increased recurrence, likely reflecting the underlying risk stratification rather than a causal protective effect. These findings support the use of individualized risk-based hepatitis B immunoglobulin strategies after liver transplant.

PMID 42885707
Read full article →
PubMedAnimals : an open access journal from MDPI2026-10-16

The IgG-to-Protein Ratio Influences the Relationship Between Brix Values and Immunoglobulin G Concentration in Bovine Colostrum.

Silva Flávio G FG, González-Cabrera Marta M, Hernández-Castellano Lorenzo E LE, Sobral Rute R et al.

This study investigated the relationship between Brix values and the nutritional and immunological composition of bovine colostrum. Colostrum samples (n = 82) were collected from Holstein-Friesian cows on four dairy farms. Dry matter (DM), solids non-fat (SNF), crude protein (CP), fat, IgG concentrations, and Brix values were determined. Correlation, regression, and receiver operating characteristic (ROC) analyses were used to evaluate associations among variables and identify a Brix cut-off for high-quality colostrum (IgG ≥ 50 g/L). Brix was positively associated with both CP (ρ = 0.90) and IgG concentration (ρ = 0.75), although the relationship between Brix and IgG was significantly influenced by the IgG/CP ratio. A robust regression model including SNF and fat provided the best prediction of Brix values (R2 = 0.98). ROC analysis identified a Brix cut-off of approximately 25%, which detected high-quality colostrum with 83% sensitivity and 76% specificity. Colostrum above this threshold had higher DM, SNF, CP, and IgG concentrations, but not fat concentration. These findings suggest that Brix values primarily reflect the soluble solids fraction of colostrum and that variation in the proportion of IgG within total protein may contribute to the variability in Brix-IgG relationships and threshold values reported among studies.

PMID 42882948
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about immunoglobulin G